Homology Medicines, Inc.

Homology is based on groundbreaking science that harnesses the naturally occurring process of homologous recombination. This non-nuclease-based approach offers clear advantages in its precision, efficiency and on-target in vivo editing of genetic mutations. Homology obtained an exclusive worldwide license to this technology platform, which is based on the pioneering research of Saswati Chatterjee, Ph.D., Professor of Virology at the Beckman Research Institute at the City of Hope in California, member of the Recombinant DNA Advisory Committee (RAC) to the Office of the Director, National Institutes of Health (NIH) and former charter member of the Therapeutic Approaches to Genetic Diseases Study Section of the NIH. Dr. Chatterjee and her team led the first adeno-associated virus (AAV) vector-mediated gene transfer studies into human hematopoietic stem cells and subsequently identified and isolated a series of naturally-occurring AAVs from human CD34+ cells.

Read full press release »

 

Company Photo

Company Photo

Dr. Saswati Chatterjee (right) and Dr. Laura Smith, Homology scientific co-founders from the City of Hope.

Meet the Team

Homology’s world-class management team has successfully developed and commercialized therapies for patients with rare diseases. Think you have what it takes to thrive in this environment? Contact us about careers at Homology.